| Serial Number | 79340792 |
| Word Mark | BICYCLE ALPHA RADIONUCLIDE THERAPY |
| Filing Date | Friday, February 25, 2022 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, September 12, 2023 |
| Registration Number | 7159642 |
| Registration Date | Tuesday, September 12, 2023 |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, June 27, 2023 |
| Goods and Services | Pharmaceuticals, for use in the treatment and prevention of disease in the field of oncology for both solid and liquid tumours, for use in the treatment and prevention of metabolic disease, urology and renal disease, in the cardiovascular field, in the field of hematology, for use in the treatment and prevention of respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of oncology; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of ophthalmology; pharmaceutical products and preparations for use in the treatment and prevention of disease in the field of neurology; anti-infective pharmaceutical products and preparations; pharmaceutical products and preparations for the treatment and/or prevention of respiratory disease; pharmaceutical products and preparations for the treatment and/or prevention of cardiovascular disease; pharmaceutical products and preparations for the treatment and/or prevention of metabolic disease; pharmaceutical products and preparations for the treatment and/or prevention of viral infections; pharmaceutical products and preparations for use in diagnostics and imaging, namely, clinical imaging agents; pharmaceutical products and preparations for the treatment and/or prevention of renal disease; pharmaceutical products and preparations for the treatment and/or prevention of gastrointestinal disease; pharmaceutical products and preparations for the treatment and/or prevention of muscular skeletal disease |
| Goods and Services | Medical services; medical testing for diagnostic or treatment purposes; healthcare services for the treatment and prevention of disease in the field of oncology for both solid and liquid tumours, for the treatment and prevention of metabolic disease, urology and renal disease, cardiovascular diseases, for the treatment and prevention of disease in the field of hematology, for the treatment and prevention of respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders; pharmaceutical compounding services; medical consulting services; advisory services relating to pharmaceuticals; consultancy and information services relating to pharmaceuticals, namely, medical and pharmaceutical consultation and providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; medical services in the field of oncology; medical services in the field of ophthalmology; medical services in the field of neurology; medical services in the field of anti-infectives; medical services in the field of respiratory disease; medical services in the field of cardiovascular disease; medical services in the field of metabolic disease; medical services in the field of the treatment and/or prevention of viral infections; medical services in the field of diagnostics and imaging; medical services in the field of renal disease; medical services in the field of gastrointestinal disease; medical services in the field of muscular skeletal disease; pharmaceutical compounding services in the field of oncology; pharmaceutical compounding services in the field of ophthalmology; pharmaceutical compounding services in the field of neurology; pharmaceutical compounding services in the field of anti-infectives; pharmaceutical compounding services in the field of respiratory disease; pharmaceutical compounding services in the field of cardiovascular disease; pharmaceutical compounding services in connection with metabolic disease; pharmaceutical compounding services in connection with the treatment and/or prevention of viral infections; pharmaceutical compounding services in connection with diagnostics and imaging; pharmaceutical compounding services in connection with renal disease; pharmaceutical compounding services in connection with gastrointestinal disease; pharmaceutical compounding services in connection with muscular skeletal disease; information, consultancy and advisory services relating to the aforesaid |
| Disclaimer with Predetermined Text | "ALPHA RADIONUCLIDE THERAPY" |
| Goods and Services | Scientific and technological services and research and design relating thereto, namely, scientific research, new product design services, and new study design services in the fields of the development of future human and veterinary medical treatments in the field of oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders, diagnostic preparations and clinical imaging agents; industrial analysis and research services in the fields of oncology for both solid and liquid tumors, metabolic disease, urology and renal disease, cardiovascular, hematology, respiratory, chronic and acute inflammatory disease and auto-immune disorders, gastrointestinal disease, bacterial and viral infectious disease, neurological and psychiatric disorders, diagnostic preparations and clinical imaging agents; pharmaceutical research and development services; medical research and development services; pharmaceutical testing and medical and scientific research, namely, conducting clinical trials for others; medical and scientific research, namely, conducting clinical trials for others; research and development in the field of oncology; research and development in the field of ophthalmology; research and development in the field of neurology; research and development in the field of anti-infective pharmaceuticals; research and development in the field of respiratory disease; research and development in the field of cardiovascular disease; research and development in the field of metabolic disease; research and development in the field of antiviral drugs; research and development in the field of diagnostics and imaging; research and development in the field of renal disease; research and development in the field of gastrointestinal disease; research and development in the field of muscular skeletal disease; information consultancy and advisory services relating to the aforesaid |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, May 20, 2022 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, May 20, 2022 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Friday, May 20, 2022 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Bicycletx Limited |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 99 - Other |
| Address | GB |
| Party Name | Bicycletx Limited |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 99 - Other |
| Address | GB |
| Party Name | Bicycletx Limited |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | GB |
| Event Date | Event Description |
| Monday, January 8, 2024 | FINAL DECISION TRANSACTION PROCESSED BY IB |
| Thursday, December 14, 2023 | FINAL DISPOSITION NOTICE SENT TO IB |
| Thursday, December 14, 2023 | FINAL DISPOSITION PROCESSED |
| Tuesday, December 12, 2023 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |
| Friday, December 1, 2023 | NEW REPRESENTATIVE AT IB RECEIVED |
| Tuesday, September 12, 2023 | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Tuesday, September 12, 2023 | REGISTERED-PRINCIPAL REGISTER |
| Tuesday, June 27, 2023 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, June 27, 2023 | PUBLISHED FOR OPPOSITION |
| Sunday, June 25, 2023 | NOTIFICATION PROCESSED BY IB |
| Wednesday, June 7, 2023 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Wednesday, June 7, 2023 | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB |
| Wednesday, June 7, 2023 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Monday, May 22, 2023 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Friday, April 21, 2023 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Thursday, April 20, 2023 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, April 20, 2023 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Monday, November 21, 2022 | REFUSAL PROCESSED BY IB |
| Friday, October 28, 2022 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Friday, October 28, 2022 | REFUSAL PROCESSED BY MPU |
| Saturday, September 24, 2022 | CHANGE OF NAME/ADDRESS REC'D FROM IB |
| Sunday, September 11, 2022 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Saturday, September 10, 2022 | NON-FINAL ACTION WRITTEN |
| Wednesday, September 7, 2022 | ASSIGNED TO EXAMINER |
| Tuesday, May 24, 2022 | APPLICATION FILING RECEIPT MAILED |
| Friday, May 20, 2022 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, May 19, 2022 | SN ASSIGNED FOR SECT 66A APPL FROM IB |